Cagrisema

CagriSema is a combination drug that brings together two injectable peptides that each act on appetite and metabolism: cagrilintide, a long-acting analogue of the hormone amylin that also engages calcitonin receptors, and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist already marketed for diabetes and weight management under other brand names ^[1][3]. By combining an amylin-based agent with a GLP-1 agonist, the product is designed to recruit two complementary satiety pathways at once ^[2][4].

The medicine is being developed by the Danish pharmaceutical company Novo Nordisk and is administered as a once-weekly injection under the skin ^[1]. It has been positioned as a potential successor to earlier incretin-based therapies for obesity and type 2 diabetes ^[3]. Its efficacy and safety have been assessed in the phase 3 REDEFINE program, and as of 2026 it is an investigational agent that has completed pivotal trials but has not yet received marketing approval ^[1].

In REDEFINE 2, a double-blind, placebo-controlled trial in adults who had both excess weight and type 2 diabetes, once-weekly cagrilintide-semaglutide lowered body weight by roughly 14 percent over 68 weeks, compared with about 3 percent on placebo, while also markedly improving glycated hemoglobin, a long-term measure of blood sugar ^[1]. Companion studies in the same program evaluated the combination in people with obesity who did not have diabetes. Across these trials the most common side effects were gastrointestinal, such as nausea, and were generally mild to moderate and temporary ^[1].

CagriSema is one of several next-generation, multi-target peptide therapies competing to extend the weight-loss and glucose-lowering gains achieved by semaglutide and the dual agonist tirzepatide ^[2][4]. Reviews group it with other emerging agents, including unified GLP-1 and amylin molecules and triple hormone agonists, that seek to combine the actions of several gut and pancreatic hormones in a single treatment ^[2][4].

Because it is still under review, CagriSema is not yet available as an approved prescription product, and its regulatory status, labeling, and long-term outcomes remain to be finalized ^[1][4]. Like its component drugs, it is a biologic peptide delivered by subcutaneous injection rather than an oral tablet ^[3].

As with other incretin-based therapies, gastrointestinal side effects like nausea, vomiting, and diarrhea are the most common, and they tend to be worse during dose escalation. The class carries warnings about pancreatitis and, from rodent data, thyroid C-cell tumors, so it is avoided in people with a history of medullary thyroid cancer or MEN 2. Because it is still investigational, the full long-term safety picture is still being established.